Funding Partners

The International Prophylaxis Study Group (IPSG) is grateful for the support of our funding partners, whose contributions help advance research, education, and collaboration in the field of hemophilia and inherited bleeding disorders. Their commitment enables IPSG to continue its work in developing evidence-based treatment strategies, improving patient outcomes, and driving innovation in hemophilia care.

Funding for the 2025 – 2026 activities of the IPSG is provided by Independent Educational grants from Pfizer, Sanofi , Sobi, and Takeda to the Hospital for Sick Children (“SickKids”) Foundation.

We appreciate the ongoing support from the following organizations: